bioAffinity Technologies' CyPath® Lung Case Study Demonstrates Efficacy, Helps Patient Avoid Invasive Biopsy

summarizeSummary

bioAffinity Technologies released a new clinical case study for its CyPath® Lung test, showing it provided actionable results for a high-risk patient, helping avoid an invasive lung biopsy.

check_boxKey Events

• New Clinical Case Study Released

  bioAffinity Technologies announced a new clinical case study for its noninvasive lung cancer test, CyPath® Lung, on March 17, 2026.

• CyPath® Lung Aids Diagnostic Pathway

  The case study highlights how CyPath® Lung improved diagnostic clarity for a 71-year-old high-risk patient with multiple pulmonary nodules, supporting the physician's decision to defer an invasive lung biopsy.

• Avoids Invasive Procedures and Lowers Costs

  The test's 'Unlikely Malignancy' result allowed for a follow-up CT scan, which showed the suspicious nodules had resolved, demonstrating the test's potential to reduce patient anxiety and healthcare costs by avoiding unnecessary invasive procedures.

• Reinforces Product Value Amidst Financial Concerns

  This positive product development comes shortly after the company disclosed a going concern warning in its 2025 10-K, making any positive news regarding its core product's efficacy and market value more significant.

auto_awesomeAnalysis

This 8-K announces a new clinical case study highlighting the benefits of bioAffinity Technologies' flagship product, CyPath® Lung. The case study demonstrates the test's ability to provide actionable results for high-risk patients with pulmonary nodules, potentially helping them avoid costly and invasive procedures. This positive product news is particularly important given the company's recent disclosure of a going concern warning in its 2025 10-K filing on March 14, 2026. Positive developments for its core diagnostic product could help improve investor sentiment and provide a pathway for future revenue generation, which is crucial for a company facing financial challenges and seeking shareholder approval for a reverse stock split to maintain its Nasdaq listing.